Artificial Development, Inc. Company Profile

21:03 EST 23rd January 2019 | BioPortfolio

Artificial Development is building CCortex™, an simulation of the Human Cortex and peripheral systems, running on a computer cluster. CCortex will enable the development an array of systems and products that can replicate, partially or completely, some of the primary characteristics of Human Intelligence. Those characteristics include pattern recognition, verbal and visual communication, knowledge acquisition, and conscious-approximate decision-making capabilities.


2390 El Camino Real
Palo Alto
United States of America



News Articles [595 Associated News Articles listed on BioPortfolio]

Artificial synaptic device simulating the function of human brain

Researchers have developed a high-reliability artificial electronic synaptic device that simulates neurons and synapses. The finding is expected to be utilized in the development of artificial intelli...

Two Artificial Intelligence Companies Partner to Take on DMD and Orphan Diseases

For many companies, artificial intelligence has become a key tool in drug development. Now, two companies that specialize in AI-backed drug development are teaming up to take on the rare disease known...

Researchers generate crucial life event in artificial mouse embryo.

Understanding the inception of embryonic development is important as it may help explain why some human pregnancies fail at an early stage, however, key events after the implantation of the embryo are...

Guiding the Smart Growth of Artificial Intelligence

NewsNew study presents an overview of progress on the "Barcelona Declaration for the Proper Development and Usage of Artificial Intelligence in Europe."Co

How Artificial Intelligence Will Affect Healthcare and Drug Prices

Artificial intelligence (AI) is the development within computer systems of the ability to perform tasks that have traditionally required human intelligence. Examples of AI applications include visual ...

Cambridge Biotech Targets Artificial Pancreas Market With Fast Insulin and Stable Glucagon

UK biotech Arecor has raised €6.7M to help fund development of its extra-fast insulin and stable glucagon products for people with insulin-dependent diabetes. The speed of action of insulin has been...

Scientists move closer towards creating artificial embryos – Deccan Chronicle

Deccan ChronicleScientists move closer towards creating artificial embryosDeccan ChronicleAn international team of scientists has moved closer to creating artificial embryos after using mouse stem cel...

Artificial Intelligence to Improve Drug Combination Design

NewsA new auto-commentary looks at how an emerging area of artificial intelligence can be used to improve drug development and personalized medicine.

PubMed Articles [1305 Associated PubMed Articles listed on BioPortfolio]

Artificial synapses based on nanomaterials.

Artificial synapses emulate biological synaptic signals in neuromorphic systems to attain brain-like computation and autonomous learning behaviors in non-von-Neumann systems. Several classes of materi...

Highly Compact Artificial Memristive Neuron with Low Energy Consumption.

Neuromorphic systems aim to implement large-scale artificial neural network on hardware to ultimately realize human-level intelligence. The recent development of nonsilicon nanodevices has opened the ...

Artificial intelligence in drug development: present status and future prospects.

Artificial intelligence (AI) uses personified knowledge and learns from the solutions it produces to address not only specific but also complex problems. Remarkable improvements in computational power...

The Current State of Artificial Intelligence in Ophthalmology.

Artificial Intelligence (AI) is a branch of computer science that deals with the development of algorithms that seek to simulate human intelligence. We provide an overview of the basic principles in A...

The artificial placenta: Continued lung development during extracorporeal support in a preterm lamb model.

An artificial placenta (AP) utilizing extracorporeal life support (ECLS) could avoid the harm of mechanical ventilation (MV) while allowing the lungs to develop.

Clinical Trials [2294 Associated Clinical Trials listed on BioPortfolio]

Safety and Efficacy of an Artificial Tear for the Treatment of Dry Eye

The efficacy, safety and acceptability of a new artificial tear in subjects with dry eye will be compared to a currently-available artificial tear

A Comparison of Orally Pilocarpine and Artificial Saliva in Xerostomy Treatment

The purpose of this study is to assess and compare the safetyness and efficacy of pilocarpine drops versus artificial saliva as symptomatic treatment for dry mouth and dry eyes caused by...

The Visual Effect of an Investigational Artificial Tear in the Tear Layer.

The purpose of this study is to investigate how the addition of a new artificial tear product when applied to the tear layer affects contrast sensitivity and optical aberrations over time....

Effects of Artificial Sweetener on Gastrointestinal (GI) Peptide Secretion

The purpose of this study is to examine the influence of artificial sweeteners (aspartame, acesulfame K, sucralose) and carbohydrate sugars (glucose, fructose) on the release of gastrointe...

Effects of Dietary Interventions on Serum and Macrophage Atherogenicity

While previous atherosclerosis-related studies have focused mainly on the atherogenicity of lipids, the proposed study aims to investigate the effects of other dietary factors, i.e. monosa...

Companies [610 Associated Companies listed on BioPortfolio]

Artificial Development, Inc.

Artificial Development is building CCortex™, an simulation of the Human Cortex and peripheral systems, running on a computer cluster. CCortex will enable the development an array of systems and prod...

SynCardia Systems, Inc.

SynCardia Systems, Inc. is the Tucson-based manufacturer of the world’s only FDA, Health Canada and CE approved Total Artificial Heart: the SynCardia temporary Total Artifici...


MyoPowers Medical Technologies SA was founded by Dr Piergiorgio Tozzi, MD, of the University Hospital of Lausanne (CHUV), Switzerland and Professor Daniel Hayoz of the Cantonal Ho...

Artificial Cell Technologies, Inc.

Artificial Cell Technologies, Inc. is an early-stage biomedical nanotechnology company founded in 2002 to commercialize applications of a new proprietary technology platform involving designed polypep...

Artificial Life, Inc.

Artificial Life, Inc. is a pioneer in artificial intelligence and mobile technology. We are a public US corporation (public since 1998; NASDAQ OTC: ALIF) with global headquarters in Hong Kong. The Com...

More Information about "Artificial Development, Inc." on BioPortfolio

We have published hundreds of Artificial Development, Inc. news stories on BioPortfolio along with dozens of Artificial Development, Inc. Clinical Trials and PubMed Articles about Artificial Development, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Artificial Development, Inc. Companies in our database. You can also find out about relevant Artificial Development, Inc. Drugs and Medications on this site too.

Quick Search


Relevant Topics

A diagnostic test is any kind of medical test performed to aid in the diagnosis or detection of disease. For example: to diagnose diseases to measure the progress or recovery from disease to confirm that a person is free from disease Clin...

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...

Corporate Database Quicklinks

Searches Linking to this Company Record